Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.

Fitzgerald DJ, Fitzgerald GA.

Circ Res. 2013 Jan 4;112(1):174-94. doi: 10.1161/CIRCRESAHA.111.300271.

2.

Pharmacogenetics of the antiplatelet effect of aspirin.

Würtz M, Kristensen SD, Hvas AM, Grove EL.

Curr Pharm Des. 2012;18(33):5294-308. Review.

PMID:
22724416
3.

Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.

Nylander S, Wågberg F, Andersson M, Skärby T, Gustafsson D.

J Thromb Haemost. 2015 Aug;13(8):1494-502. doi: 10.1111/jth.13027. Epub 2015 Jul 23.

PMID:
26096765
4.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
5.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
6.

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.

Raju NC, Eikelboom JW, Hirsh J.

Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):766-80. doi: 10.1038/ncpcardio1372. Epub 2008 Oct 28. Review.

PMID:
18957959
7.

High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.

Trenk D, Kristensen SD, Hochholzer W, Neumann FJ.

Thromb Haemost. 2013 May;109(5):834-45. doi: 10.1160/TH12-08-0588. Epub 2012 Dec 13. Review.

PMID:
23238773
8.

Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.

Zaccardi F, Pitocco D, Willeit P, Laukkanen JA.

Atherosclerosis. 2015 Jun;240(2):439-45. doi: 10.1016/j.atherosclerosis.2015.04.015. Epub 2015 Apr 16. Review.

PMID:
25897998
9.

How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; European Platelet Academy..

Thromb Haemost. 2015 Jan;113(1):37-52. doi: 10.1160/TH14-03-0238. Epub 2014 Sep 18. Review.

PMID:
25231675
10.

Clinical use of aspirin in ischemic heart disease: past, present and future.

De Caterina R, Renda G.

Curr Pharm Des. 2012;18(33):5215-23. Review.

PMID:
22724410
11.

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.

Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D.

Thromb Haemost. 2014 Aug;112(2):342-51. doi: 10.1160/TH13-10-0874. Epub 2014 Apr 10.

PMID:
24718389
12.

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.

Bernlochner I, Byrne RA, Kastrati A, Sibbing D.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):999-1014. doi: 10.1586/erc.11.80. Review.

PMID:
21878045
13.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
14.

Clopidogrel: the data, the experience, and the controversies.

Sadanandan S, Singh IM.

Am J Cardiovasc Drugs. 2012 Dec 1;12(6):361-74. doi: 10.2165/11636340-000000000-00000. Review.

PMID:
23057989
15.

Development and clinical use of prasugrel and ticagrelor.

Ahmad S, Storey RF.

Curr Pharm Des. 2012;18(33):5240-60. Review.

PMID:
22724412
16.

Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?

Cattaneo M.

J Thromb Haemost. 2012 Mar;10(3):327-36. doi: 10.1111/j.1538-7836.2011.04602.x. Review.

17.

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.

Maree AO, Fitzgerald DJ.

Circulation. 2007 Apr 24;115(16):2196-207. Review. No abstract available.

18.

[The ISAR-SAFE study].

Capranzano P, Castiglioni B.

G Ital Cardiol (Rome). 2015 Jun;16(6):331-5. doi: 10.1714/1934.21024. Italian. No abstract available.

PMID:
26156693
19.

Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.

Consuegra-Sánchez L, López-Palop R, Cano P, Carrillo P, Picó F, Villegas M, Sanchis J, Kaski JC.

J Thromb Haemost. 2013 Feb;11(2):379-81. doi: 10.1111/jth.12073. No abstract available.

20.

High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.

Bernlochner I, Jaitner J, Fries V, Dommasch M, Mayer K, Ott I, Langwieser N, Fusaro M, Laugwitz KL, Kastrati A, Ibrahim T.

Vasa. 2016;45(2):155-61. doi: 10.1024/0301-1526/a000510.

PMID:
27058802

Supplemental Content

Support Center